spacer
home > ebr > autumn 2017 > homing in
PUBLICATIONS
European Biopharmaceutical Review

Homing In

Since the first daVinci surgical systems began marketing in 1999 and the following acquisition of Computer Motion by Intuitive Surgical in 2003, very few innovations have been made in the field. Initial adoption of such technology was limited and most surgeons were highly sceptical about its future. However, over the span of 15 years, Intuitive Surgical transformed robotic surgery from an interesting market experiment to an established technique. Today, analysts project exponential growth in the years to come, and nobody doubts that the future is in robotics.

As initial patents expire and new technologies are developed, a rising number of modern robotic surgical systems have been, or are about to be, launched. The competition for shares will be fierce.

Perfecting Platforms

The market might seem big enough for everybody, but the reality could be more complex. For most hospitals, adopting a given robotic surgical platform is a big decision and is not easily reversible, as it involves significant costs and efforts, such as staff training. Due to the requirements for an increased number of operating rooms and storage, a costly multi-platform-adapted staff and a complex maintenance organisation, working with two different types of robotic platforms is also unlikely. However, bigger hospitals that might actually need to utilise several robotic platforms could reduce costs by taking advantage of economies of scale.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Andre Faure has a surgical background and decided to interrupt his early medical career to develop new surgical devices. For more than 15 years, he has led several multi-national R&D programmes in the field where he has developed robotic surgical instruments, including devices for treating atrial fibrillation and liver cancer. Andre is also the founder of Trod Medical, a company created around one of his inventions – a robotic device specifically developed for localised prostate cancer treatment.
spacer
Dr Andre Faure
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Navigating the new Clinical Trial Regulation with DIA

For those stakeholders involved with clinical trials in Europe, the new Clinical Trial Regulation to be introduced in 2019 will have a dramatic impact. The aim of the change in regulation is to increase the efficiency of all trials in Europe, as well as promoting research while avoiding the duplication of clinical trials
More info >>

White Papers

Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014

Synergy Research Group

The Orange Paper is an analytical report about the clinical trials market in Russia, published quarterly by the contract research organization Synergy Research Group. The first edition of Orange Paper was released in 2006, and at the moment 31 issues have already published. Now, thanks to Synergy Group Ukraine, obtaining information about the market of clinical trials in Ukraine has become possible. In Ukraine, during the period from 1996 to 2013, applicants had obtained 3,864 positive conclusions about the possibility of conducting clinical trials of drugs, both for domestic and foreign manufacturers, including conduct of multinational multi-center clinical trials (hereinafter – MMCTs)
More info >>

 
Industry Events

Biotech Showcase 2018

8-10 January 2018, Hilton San Francisco, Union Square, CA 94102 USA

Biotech Showcase™ is an investor and partnering conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement